Inhaled fluticasone propionate impairs pulmonary clearance of  in mice by unknown
Patterson et al. Respiratory Research 2012, 13:40
http://respiratory-research.com/content/13/1/40RESEARCH Open AccessInhaled fluticasone propionate impairs pulmonary
clearance of Klebsiella Pneumoniae in mice
Craig M Patterson1, Richard L Morrison1, Alain D’Souza1, Xu S Teng2 and Kyle I Happel1,3*Abstract
Background: Recent trials demonstrate increased pneumonia risk in chronic obstructive pulmonary disease
patients treated with the inhaled corticosteroid (ICS) fluticasone propionate (FP). There is limited work describing FP
effects on host defenses against bacterial pneumonia.
Methods: C57BL/6 mice received daily, nose-only exposure to nebulized FP or vehicle for 8 days, followed by
pulmonary challenge with Klebsiella pneumoniae. Bacterial burden, phagocytosis, leukocyte recruitment, cytokine
expression, nitric oxide release, and survival were measured.
Results: Inhaled FP increased bacterial burden in lungs and blood 48 h after infection but affected neither in vivo
phagocytosis of bacteria by alveolar macrophages (AM) nor alveolar neutrophil recruitment. AM from FP-treated
mice showed impaired expression of infection induced TNF-alpha, IP-10 (CXCL-10), and interleukin 6 (IL-6), and AM
also showed a trend towards impaired intracellular pathogen control following in vivo infection. In vitro FP
treatment resulted in a dose-dependent impairment of cytokine expression by AM. Furthermore, infection-induced
nitric oxide (but not hydrogen peroxide) production was impaired by FP in vivo and in vitro. FP decreased survival
in this model.
Conclusions: Exposure to inhaled FP impairs pulmonary clearance of K. pneumoniae in mice, an effect associated
with greater systemic bacteremia and death. Decreased AM cytokine and nitric oxide expression parallel the failure
to control infection. These results support the study of ICS effects on human pulmonary host defenses.Introduction
The immune modulatory effects of inhaled corticoster-
oids (ICS) on inflammatory airway diseases are well-
recognized, and they are widely used in the treatment of
asthma [1]. In recent years, ICS have also been increas-
ingly utilized in the treatment of chronic obstructive
pulmonary disease (COPD) and other pulmonary disease
states [2]. Several large, randomized trials have demon-
strated significant clinical benefits of ICS, such as fewer
acute COPD exacerbations, better lung function, and
improved symptom scores [3-5]. Despite these benefits,
multiple trials have now revealed an increased incidence
of pneumonia diagnosis in COPD patients given ICS,* Correspondence: khappe@lsuhsc.edu
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reproduction in any medium, provided the orparticularly fluticasone propionate [6-9]. Despite the
large numbers of patients in these trials, heterogeneity
in data collection and the lack of a prospective definition
for pneumonia confound a definitive causal link between
ICS use and pneumonia.
The effects of glucocorticoids (both systemic and
inhaled) on airways inflammation are well-documented
and have led to the widespread use of these medications
in the treatment of obstructive lung diseases. A meta-
analysis of 18 randomized controlled trials (totaling
nearly 17,000 patients) to ascertain the risk of pneumo-
nia associated with ICS use by COPD patients concluded
that ICS use is associated with a significantly increased
risk of serious pneumonia, without a significantly
increased risk of death [10]. A subsequent trial studying
a lower dose of FP (250mcg twice daily) in COPD
patients also reported increased pneumonia rates in sub-
jects receiving ICS [8]. While strict microbiologic or
radiographic criteria were not required for diagnosing
pneumonia in these trials, it is intuitive that severalral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ICS given their potent anti-inflammatory effects.
We hypothesized that clinically relevant doses of
inhaled FP administered via nose-only aerosolized expos-
ure alters innate pulmonary defenses to live bacterial
challenge with a typical pneumonia pathogen. We chose
a murine model of pulmonary infection with Klebsiella
pneumoniae given our familiarity with this model and a
subsequent analysis of the TORCH trial data identifying
this organism as an etiologic agent of pneumonia in
patients treated with ICS [11].
Materials and methods
Mice
Specific pathogen-free male C57BL/6 mice (Charles
River Laboratories; Wilmington, MA) between the ages
of 6 – 8 weeks were used for all experiments. All mice
were housed in the LSUHSC vivarium and treated in ac-
cordance with institutional guidelines. Mice received
food and water ad libitum during 12-hour light/dark
cycles. All procedures were approved by the LSUHSC
Institutional Animal Care and Use Committee.
Fluticasone propionate administration and intratracheal
injection
FP powder (Sigma, St. Louis, MO) was resuspended at a
concentration of 300 μg/mL in sterile saline with 0.17%
vol/vol Tween-80. All mice received daily 20 minute
exposures to nebulized FP solution (or vehicle control)
via a nose-only aerosolized delivery (InExpose system;
SCIREQ, Montreal, QC, Canada) for eight successive
days. This dosing was modeled after a previously pub-
lished mouse FP study and is felt to approximate a 1 mg
daily dose of FP in humans [12]. After the eighth daily
exposure, mice were anesthetized by intraperitoneal in-
jection of ketamine-xylazine solution and underwent
intratracheal administration of 1x104 CFU Klebsiella
pneumoniae (serotype 43816; ATCC, Manassas, VA).
n ≥ 8 per group for all in vivo experiments.
Blood, lung, and bronchoalveolar lavage harvest
At designated time points, mice were anesthetized with
isofluorane and killed by diaphragmatic interruption.
Whole blood was obtained by right ventricular puncture.
Lungs were removed en bloc and homogenized in 1 ml
of sterile PBS for microbiological studies, or in 1 mL of
buffer RLT (RNeasy Mini Kit; Qiagen, Valencia, CA) for
mRNA isolation, or in 1 mL of PBS with 0.1% Triton X-
100 and a protease-inhibitor cocktail (Complete Mini,
Roche Diagnostics; Indianapolis, IN) for protein analysis.
Bronchoalveolar lavage (BAL) cells were retrieved by lav-
age of removed lungs with PBS containing 0.1% glucose.
A total of 10 mL lavage was performed in 1 mL aliquots.The initial 1 mL BAL aliquot was used for cytokine
analysis.
Bacteriology
Bacterial CFU in blood and lungs were determined by
plating 100 μl of whole blood (and its serial dilutions) or
homogenized lung (and its serial dilutions) on MacCon-
key agar plates (Oxoid; Basingstoke, Hampshire, Eng-
land) followed by overnight incubation.
In vivo phagocytosis
Mice were administered 1 × 109 eGFP-Klebsiella pneu-
moniae (serotype 43816, a kind gift from Steven Clegg,
University of Iowa) by intratracheal inoculation. After 2
hours, mice were killed and BAL was performed to re-
trieve alveolar macrophages. Cells were centrifuged at
100 × g and washed 3 times to remove free bacteria. The
fluorescence of phagocytosed organisms within alveolar
macrophages was then measured by flow cytometry
(FACSCalibur™; BD Biosciences, San Jose, CA). The per-
centage of cells phagocytosing bacteria and the mean
fluorescence intensity (MFI) of each cell were recorded.
Examination of BAL cells by deconvolution microscopy
confirmed that fluorescent organisms were intracellular,
as very few fluorescing AM (<1%) showed cell surface-
associated bacteria.
Cell culture
AM from FP and vehicle-nebulized mice were retrieved
by BAL as described above. 2x105 cells per well were
plated in 96 well plates in DMEM+10% fetal calf serum.
Cells were exposed to K. pneumoniae at a multiplicity of
infection (MOI) of 100:1. Culture supernatant was har-
vested for cytokine or reactive oxygen/nitrogen species
analysis at indicated time points.
Reactive oxygen/nitrogen species
In vitro production of hydrogen peroxide by alveolar
macrophages in response to 10nM PMA and 1 μM cal-
cium ionophore A23187 (both from Sigma) was assessed
using the fluorogenic AmplexW UltraRed reagent (Invi-
trogen; Eugene, OR) as previously described [13]. Nitric
oxide production by alveolar macrophages was assessed
by measurement of supernatant nitrite using the Griess
reaction (Parameter™ Total Nitric Oxide Assay Kit, R&D
Systems; Minneapolis, MN).
iNOS (NOS2) mRNA expression
Whole lung total RNA was isolated using the RNeasy
Mini Kit (Qiagen). 10 ng of RNA was subjected to 2-step
real-time reverse transcription and polymerase chain re-
action (RT-PCR) using a pre-developed Taqman assay
for mouse inducible nitric oxide synthase (iNOS or
A)
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Lungs were fixed by inflation with 10% formalin to visual
total capacity and embedded in paraffin. Lung sections
were mounted onto slides and stained with hematoxylin
and eosin and inspected by light microscopy at 40x and
100x magnification. The slides were evaluated by an
experienced LSUHSC Morphology and Imaging Core
microscopist without knowledge of treatment group as-
signment. Photomicrographs of representative sections
were taken. Vehicle FP
Figure 1 K. pneumoniae CFU in the lung (A) and blood (B) of FP
or vehicle-treated mice 48 hours after i.t. challenge. Mice
receiving FP for 8 consecutive days prior to infection demonstrate
significantly higher bacterial burdens in both compartments. n = 10
for each group. Lines indicate mean of each group. Results shown
are from one of three separate experiments. * p< 0.05 vs. vehicle.Statistical analysis
Comparisons between different treatment groups were
made using Student’s t-test for simple pair-wise compar-
isons. For data not normally distributed, values were
log10 transformed prior to analysis. Survival functions
were generated using Kaplan-Meier estimators, and
comparisons between Kaplan-Meier survival curves were
made using the log rank and Wilcoxon rank-sum tests.
Differences between treatment groups were accepted as
significant when p< 0.05.Results
Bacteriology
Our initial investigations sought to determine the effects
of inhaled FP on the burden of bacteria present in the
lungs and blood of mice at various intervals after an in-
fectious i.t. dose of K. pneumoniae. CFU counts from
the incubated whole-lung homogenates of FP-treated
mice at both 4 hours and 24 hours after infection were
higher than those from vehicle-treated animals, although
the differences did not meet statistical significance (data
not shown). However, experiments 48 hours after infec-
tion demonstrated a statistically significant increase in
CFU counts from both the lungs and blood of FP-treated
mice compared to vehicle-treated animals (Figure 1A
and 1B). Histologic examination of lung tissues at 24
hours post-infection revealed only small areas of peri-
bronchial neutrophil influx in control animals (Figure 2A),
whereas lungs from FP-treated mice showed frequent
and larger areas of confluent consolidation within the
lung parenchyma (Figure 2B).Phagocytosis
Resident alveolar macrophages (AM) play a key role in
the early innate response to infection in the lung. A not-
able function is their phagocytosis of free and opsonized
bacteria in the alveolar spaces. Existing data suggest vari-
able effects of different glucocorticoids on macrophage
phagocytic function [14,15]. We conducted experiments
to test the effects of inhaled FP on the in vivo phagocyt-
osis of K. pneumoniae by mouse alveolar macrophages.
The alveolar macrophages of mice exposed to FP, when
compared to vehicle-exposed animals, demonstrated no
difference in the percentage of macrophages which had
engulfed bacteria by 2 hours after pulmonary bacterial
challenge (51% vs 53%, control vs. FP, p =NS). The mean
fluorescent intensity (MFI) of AM, indicating the num-
ber of bacteria per cell, consistently trended towards a
greater amount in AM from FP-treated mice, although
differences did not achieve statistical significance after
adjustment for multiple comparisons (MFI of FP-treated
AM 127% of control AM, p = 0.09).
Cellular recruitment
Neutrophil recruitment is an essential component of the
innate immune response to bacterial infection in the
lungs. We investigated the effect of inhaled FP on neutro-
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Figure 3 BAL cell counts (A) and BAL cell differentials (B) of vehicle a
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Figure 2 Lung histology 24 hours after K. pneumoniae
infection. Lungs from control mice (A) show only patchy neutrophil
infiltrates near the airways, whereas lungs from FP-treated mice (B)
are already showing parenchymal consolidation with mild
hemorrhage at this time point. Images are 40x magnification of H&E
stained sections and are representative of findings from 4 mice in
each group.
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were no significant differences in either the total number
of leukocytes or the differential of leukocytes in BAL from
mice nebulized with FP vs. vehicle (Figure 3A and 3B).
BAL 16 hours post infection similarly showed no differ-
ence in early neutrophil recruitment (data not shown).
Cytokines
An extensive body of published research has demon-
strated the importance of cytokine-mediated cell-cell
interactions in both innate and adaptive immune
responses to lung infection. Using a 32-plex cytokine bead
array, we first analyzed whole-lung homogenates from FP
and vehicle-treated mice 16 hours after K. pneumoniae in-
fection and identified nine cytokines substantially up-
regulated in response to bacterial challenge. Of these, IP-
10, IL-6, and TNF-α showed significantly attenuated
responses to infection in FP-exposed mice (Figure 4A).
AM were then harvested from uninfected FP and vehicle-
treated mice to assess their response to in vitroK. pneumo-
niae exposure. After four hours, culture supernatant was
assayed for the same 9 cytokines. AM from FP-treated mice
expressed significantly less KC, MIP-1α, MIP-2, IL-6, LIX,
and MCP-1 compared to AM from vehicle-treated mice
(Figure 4B). To confirm the effect of FP on AM cytokine re-
lease was both direct and dose-dependent, AM from unin-
fected mice (vehicle or FP-treated) were pre-treated (2 h)
with FP (10 or 100 nM) followed by in vitro infection with
K. pneumoniae (Table 1). Results for all 32 assayed cyto-
kines are available as Additional file 1: Table S1.
Reactive oxygen/nitrogen species
Once engulfed by phagocytic cells, bacteria are subjected
to various bactericidal substances. Of such substances,
reactive oxygen/nitrogen species (ROS/RNS) are among
the most important. In light of significantly increased
bacterial burdens in FP-treated mice in our pneumonia
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Figure 4 A Cytokine expression in whole-lung homogenates 16 hours after i.t. K. pneumoniae challenge. Shown are 9 cytokines of a
32-plex bead array analysis which were significantly induced by infection. Pretreatment with inhaled FP significantly attenuated the expression of
IP-10, IL-6, and TNF-α 16 hours after infection. n = 6 per group. * p< 0.05 vs. vehicle. B Cytokine expression by murine AM before and 4 hours after
in vitro stimulation with K. pneumoniae. While most cytokines measured showed up-regulation in response to K. pneumoniae, prior exposure to
inhaled FP attenuated the expression of the majority of these. n = 6 per group. * p< 0.05 vs. vehicle + Klebs.
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in vivo and in vitro experiments to investigate FP’s effect
on AM expression of ROS/RNS. Initial experiments
showed very little measureable H2O2 in the supernatant
of K. pneumoniae-stimulated AM, whereas the phorbol
ester PMA + ionomycin induced substantial extracellular
release of H2O2. In vitro pre-treatment with FP at con-
centrations up to 1 μM had no effect on PMA-induced
expression of H2O2 by AM harvested from either FP or
vehicle-treated mice (1.32 vs. 1.49 uM H2O2 in FP vs.
control AM respectively, p =NS). Extracellular release of
nitric oxide by AM is also minimal in response to K.
pneumoniae. FP pre-treatment did, however, reduce K.
pneumoniae-induced AM nitric oxide expression in re-
sponse to LPS/IFN-γ stimulation (Figure 5A). This in vi-
tro finding was consistent with the demonstration of a
significant decrease in the in vivo expression of iNOS
mRNA in the lungs of FP-treated mice 90 minutes after
bacterial infection (Figure 5B).
Survival
Given the defects in bacterial clearance in the lungs and
blood as a result of inhaled FP exposure, we sought to
investigate the effect of inhaled FP on survival in this
model of bacterial pneumonia. Our experiments demon-
strate a significant increase in mortality in FP-treated
mice compared to vehicle-treated mice after K. pneumo-
niae infection (Figure 6).
Discussion
Here we show that a relatively brief (8 day) exposure to
inhaled fluticasone propionate impairs pulmonaryclearance of the gram negative pathogen K. pneumoniae,
a finding associated with greater systemic bacterial bur-
den and increased mortality compared to vehicle treat-
ment. This effect was associated with decreased nitric
oxide production and cytokine expression in the lungs.
To our knowledge, this is the first work to explore the
effects of inhaled corticosteroids on pulmonary host
defenses against a virulent gram negative pathogen.
There is limited evidence detailing the effects of gluco-
corticoids on pulmonary host defense against bacterial
pathogens. Adcock et al revealed a dose-dependent de-
crease in activation of the pro-inflammatory transcrip-
tion factor NF-κB in lung epithelium treated with FP
and then exposed to cytokine challenge [16]. Ek et al
showed that treating human alveolar macrophages with
FP impairs their release of cytokines in response to bac-
terial products [17]. We identified one in vivo study that
demonstrated mice treated with inhaled FP exhibit
decreased pulmonary neutrophil recruitment and
decreased recovery of M. pneumoniae after inhalational
inoculation [12]. While well-performed, these studies
have limitations. For example, alterations in cytokine ex-
pression were measured in vitro and were in response to
bacterial products rather than live bacteria. The in vivo
murine ICS study characterized pulmonary immune
responses to an atypical bacterium, one not identified as
a cause of pneumonia in ICS-treated COPD patients
[13]. Lastly, previous in vivo investigations of aerosolized
corticosteroids used whole-body exposure models, which
could result in significant systemic steroid delivery de-
pending on animal grooming behavior and the oral bio-
availability of the drug studied.
Table 1 Cytokine concentration (pg/ml) in cell culture supernatant following in vitro K. pneumoniae infection of Alveolar Macrophages
Vehicle-Exposed AM IL-6 IP-10 KC LIX MCP-1 MIP-1a MIP-1b MIP-2 TNFa
PBS 5.54 (4.54) 43.96 (2.44) 166.47 (11.12) 79.93 (15.99) 61.07 (5.78) 68.53 (4.30) 26.05 (8.24) 1,225.18 (36.94) 52.07 (0.93)
Klebseilla 2,506.37 (167.12) 122.53 (5.10) 13,917.04 (198.04) 1,518.32 (57.78) 68.74 (2.19) 10,038.19 (180.37) 9,318.00 (1,764.90) 41,802.27 (6,019.32) 2,012.61 (724.25)
Klebs+ 10 nm FP 661.80* (36.50) 125.74 (3.51) 8,254.84* (268.01) 931.97* (21.59) 47.11* (1.71) 7,731.08* (161.64) 3,795.81* (200.74) 11,881.55* (622.15) 1,141.86 (100.01)
Klebs+ 100 nm FP 472.29*# (23.18) 116.16 (6.96) 7,912.98* (271.24) 818.89* (22.82) 35.31*# (1.13) 6,674.62*# (252.86) 3,252.32*# (82.53) 11,441.20 (736.01) 1,101.10 (62.84)
FP-Exposed AM
PBS 1.00 (0) 8.99 (1.23) 84.31 (1.72) 2.59 (1.59) 43.29 (5.49) 34.76 (2.98) 3.54 (2.54) 520.03 (26.90) 19.73 (0.85)
Klebseilla 828.87 (85.73) 122.38 (10.04) 9,891.14 (525.77) 1,056.19 (55.29) 50.38 (2.22) 9,111.51 (146.05) 5,640.23 (776.27) 14,296.83 (700.94) 1,096.82 (115.99)
Klebs+ 10 nm FP 354.74* (23.31) 105.06 (5.47) 7,472.76* (459.38) 746.89* (45.01) 33.22* (1.35) 6,636.20* (378.28) 3,670.30* (228.33) 10,762.57* (557.97) 1,066.93 (71.74)
Klebs+ 100 nm FP 327.28* (27.06) 107.73 (5.09) 6,492.42 (130.07) 701.09* (44.26) 25.64*# (0.90) 5,610.73*# (188.29) 3,511.53* (121.10) 8,612.62*# (355.80) 1,029.21 (122.45)
Cytokine expression by vehicle and FP-treated murine AM 4 h after in vitro stimulation with K. pneumoniae. The top four rows show mean and (SEM) cytokine responses by AM lavaged from vehicle treated mice, and
bottom four rows are for AM from FP-treated mice. Some groups were also pre-treated in vitro for 2 h with FP (10 or 100 nM) before infection. Results suggest a dose-dependent effect of in vitro FP exposure on AM













Figure 5 A Overnight nitric oxide production by murine AM
after in vitro stimulation with LPS (100 ng/ml) and rmIFN-γ
(100 U/ml). FP pre-treatment (2 h) decreased NO production at
10nM final concentration. n = 6 per group. * p< 0.05 vs. stimulated
group without FP. B iNOS mRNA expression in the lungs of mice
90 minutes after i.t. K. pneumoniae challenge. Mice treated with FP
for 8 days demonstrated significantly less iNOS mRNA after infection
compared to vehicle-treated animals. n = 8 per group. * p< 0.05 vs.
vehicle.
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therapeutic efficacy of ICS for treating obstructive lung
disease, relatively few studies have examined the effects
of these medications on pulmonary bacterial host
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Figure 6 Survival following i.t. K. pneumoniae challenge in FP
and vehicle-treated mice. Mice receiving FP for 8 consecutive days
prior to infection demonstrate increased mortality compared to
vehicle-exposed animals. Data shown are the cumulative results of
three independent experiments. n = 34 for vehicle treatment and
n= 36 for FP treatment. * p< 0.05 vs. vehicle.measurable effects of systemic delivered corticosteroids
on pulmonary responses to infectious agents such as P.
aeruginosa, S. aureus, L. pneumophilia, and L. monocyto-
genes,[18-22] we found only a handful of studies detail-
ing the effects of inhaled corticosteroids on the
pulmonary host response. Chu et all found that FP
impairs M. pneumoniae adhesion to epithelial cells [12].
Using a murine model of pneumonia similar to our
current study, Barbier et al recently showed decreased
airway epithelial cell adhesion by Streptococcus pneumo-
niae and Haemophilus influenzae in mice receiving a
bolus dose of FP at time of infection [23]. By reducing
epithelial cell expression of the platelet activating factor
receptor (PAFR), FP decreased phosphorylcholine-
mediated pathogen binding to PAFR. Interestingly, the
pathogen in our current study, K. pneumoniae, does not
express surface phosphorylcholine [24]. Given a recent
analysis of the TORCH data demonstrating that K. pneu-
moniae was one of the four most commonly identified
pneumonia pathogens in the COPD study population
[11], we speculate that differences in pathogen charac-
teristics may be critical in determining the effects of ICS
on host susceptibility to bacterial pneumonia.
Alveolar macrophages play an important role in the
initiation and orchestration of the acute response to
lower respiratory tract infection, and they are respon-
sible for the initial phagocytosis of deposited organisms.
We were unable to demonstrate a defect in the in vivo
capacity for alveolar macrophages to ingest fluores-
cently-labeled bacteria following FP treatment. These
results contrast with earlier reports showing that in vitro
phagocytosis of zymosan particles by sheep and rat al-
veolar macrophages is impaired by some glucocorticoids
[14,15]. Key differences between prior studies and our
current work include the in vivo study of phagocytosis,
the use of live bacterial challenge, inhaled delivery of
glucocorticoids, and the use of FP. Conversely, our flow
data did show a trend (p = 0.09) towards more bacteria
within AM lavaged from FP-treated mice, and we specu-
late this may represent a defect in early intracellular kill-
ing in vivo (as discussed separately). Nonetheless, we
conclude that the initial phagocytosis of K. pneumoniae
by AM’s is unaffected by our FP inhalation model.
Neutrophil influx is the histologic hallmark of acute
bacterial pneumonia. Several studies have documented
the importance of neutrophil recruitment in the host re-
sponse to this infection [25,26]. Our results demonstrate
increased lung parenchymal infiltration with neutrophils
in FP-treated mice, likely a result of the increased bur-
den of infection at this time point. Interestingly, we
observed equivalent alveolar neutrophil recovery (by lav-
age) in FP and vehicle groups at this time point. These
results are likely due a substantial percentage of the
recruited neutrophils in the FP-mice being within the
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trophil numbers are equivalent. At the least, these
current results do not suggest a substantial quantitative
defect in pulmonary neutrophil recruitment as a result
of inhaled steroid treatment. Prior studies of steroids
and pulmonary neutrophil recruitment are heteroge-
neous, employing various steroid agents, routes of ad-
ministration, and inflammatory/infectious stimuli
[12,22,27,28]. Given their diversity, it is not surprising
that some studies show decreased pulmonary neutrophil
recruitment while others do not. Our current work
expands the knowledge of inhaled glucocorticoid effects
on pulmonary innate immunity by demonstrating no
clear modulation of neutrophil recruitment to live gram
negative bacterial challenge, despite clear effects on lung
bacterial clearance. This in vivo observation is particu-
larly interesting in light of our in vitro data showing sig-
nificant and dose-dependent inhibition of the neutrophil
CXC chemokines MIP-2, LIX, and KC as secreted by
AM 4 hours after bacterial challenge. However, the ex-
pression of the same chemokines in vivo was unaffected
by FP exposure. We speculate that either 1) the differen-
tial burden of infection in vivo or 2) steroid-insensitive
counter-regulatory mechanisms in vivo account for our
finding of equivalent pulmonary neutrophil recruitment
in FP-treated mice.
An important mechanism of bacterial killing is the
host generation of reactive oxygen and nitrogen species
[29,30]. Alveolar macrophage H2O2 production in re-
sponse to PMA/I was unaffected by FP at doses up to
1 μM in our investigations, suggesting that this pathway
is not steroid-sensitive. Alternatively, nitric oxide expres-
sion was inhibited by low doses of FP as demonstrated
by our in vitro results. These findings are consistent with
prior work showing decreased NOS2 induction by dexa-
methasone [21,31-33]. Our in vivo work extends these
findings to live bacterial challenge by showing decreased
iNOS mRNA in the lungs of FP-treated mice, and we
speculate that the trend toward an increased number of
bacteria found within AM from FP-treated mice may be
related to their in vivo impairment of nitric oxide pro-
duction during bacterial infection. While our in vitro
data suggest that AM are an important cell population
with decreased NO production, we speculate that nu-
merous cell lines, including airway epithelial cells, may
exhibit impaired NO expression as a result of ICS [34].
Our current study has important limitations. First, this
is an animal study using a well-accepted model of pneu-
monia - one which causes mortality in a small but repro-
ducible percentage of normal animals. By contrast, human
trials show that the frequency of COPD exacerbations is
diminished by ICS, and survival in the TORCH trial
trended in favor of ICS treatment. Hence, we strongly cau-
tion against interpreting that these results can be extendedto (or are representative of) ICS use in humans. Second,
while our FP delivery was inhaled, we cannot exclude sys-
temic FP effects in our model, particularly as a cause of
increased bacterial burden in the bloodstream. While
impaired lung bacterial clearance may be due to local FP
effects, the inability to control systemic dissemination
could also be attributable to extra-pulmonary effects of FP,
since systemic effects of ICS are well-documented [35,36].
Lastly, while our data show defects in pulmonary cytokine
responses and nitric oxide production, our in vitro studies
are limited to AM and may not address other important
cells, such as airway epithelium, in which host defense
function is impaired.
Conclusion
In summary, we demonstrate that a brief, 8-day expos-
ure to inhaled FP interferes with normal murine innate
pulmonary host defenses against the virulent gram nega-
tive pathogen K. pneumoniae, and this treatment leads
to greater bacteremia and death. We believe that these
results support the validity of clinical observations show-
ing an increased risk of pneumonia in COPD patients
treated with ICS. Given the widespread clinical use of
ICS, further characterization of ICS effects on human
pulmonary host defenses is warranted.
Additional file
Additional file 1 Table S1. Whole lung homogenate levels of cytokines
16 hours after K. pneumoniae infection. Data are expressed as pg/mg
protein and are shown as mean (+/- SEM). FP = fluticasone propionate.
* p < 0.05 vs. vehicle control.
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